netFormulary
 Report : Medicines with links to NICE 22/10/2020 10:43:07

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Non Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Non Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA 455: Adalimumab, etanercept and ustekinumab for treating palque psoriasis in children and young people
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Non Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 40mg/1ml 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Formulary NICE TA52: Thrombolysis in MI
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Axitinib 08.01.05 Non Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Non Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Non Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azathioprine 01.05.03 Formulary Crohn’s disease managment
Azathioprine 01.05.03 Formulary Ulcerative Colitis management
Basiliximab 08.02.02 Non Formulary NICE TA99: Immunosuppressives in renal transplant (Children)
Basiliximab 08.02.02 Non Formulary NICE TA85: Immunosuppressives in renal transplant (Adults)
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01 Non Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Non Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bivalirudin 02.08.01 Non Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Boceprevir 05.03.03.02 Non Formulary NICE TA253: hepatitis
Bortezomib 08.01.05 Non Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Non Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib 08.01.05 Non Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Non Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bosutinib 08.01.05 Non Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Brodalumab 13.05.03 Formulary NICE TA 511: Brodalumab for Treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Non Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Capecitabine 08.01.03 Non Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Non Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Non Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Cetuximab 08.01.05 Non Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA145: Head and neck cancer - cetuximab
Ciclosporin 11.99.99.99 Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary Cladribine tablets for treating relapsing–remitting multiple sclerosis NICE TA493
Clopidogrel 02.09 Formulary NICE CG94: Unstable angina and NSTEMI: early management
Clopidogrel 02.09 Formulary NICE CG172: Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Crizotinib 08.01.05 Non Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Non Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Dabigatran 02.08.02 Formulary Drug Safety Update September 2008: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Non Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Non Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Dasabuvir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Non Formulary NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Non Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Non Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Non Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Non Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl Fumarate 13.05.03 Formulary NICE TA 475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole 200mg MR 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Doxorubicin 08.01.02 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dupilumab 13.05.03 Formulary NICE TA: Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir/Grazoprevir 05.03.03.02 Non Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Non Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.05 Formulary NICE TA 471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Non Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Non Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Non Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Non Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Non Formulary NICE CG114: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Eribulin 08.01.05 Non Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Non Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Non Formulary NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Erlotinib 08.01.05 Non Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Non Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Non Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etelcalcetide 06.06.01 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Non Formulary NICE TA348: Preventing Rejection in Liver Transplant
Everolimus 08.01.05 Non Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Non Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Non Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Non Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Non Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Glatiramer Acetate 08.02.04 Formulary NICE CG32: Glatiramer for the treatment of MS
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis
Idelalisib 08.01.05 Non Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Infliximab 01.05.03 Non Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Non Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 13.05.03 Formulary NICE: Biosimilars Position Statement
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta 08.02.04 Non Formulary NICE TA32: Interferon Beta for MS
Ipilimumab 08.01.05 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Non Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Non Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ixekizumab 13.05.03 Formulary NICE TA 442: Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.01 Non Formulary NICE CG165: Chronic Hepatitis B
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Non Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Mannitol inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mepolizumab 03.04.02 Formulary NICE TA431 Mepolizumab for treating severe refractory eosinophilic asthma
Mercaptopurine 01.05.03 Formulary Crohn’s disease management
Mercaptopurine 01.05.03 Formulary Ulcerative Colitis management
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Milrinone 02.01.02 Non Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naloxegol 01.06.06 Formulary NICE TA345
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Non Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Non Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Non Formulary NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Non Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Non Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nivolumab 08.02.04 Non Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Non Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Non Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Obeticholic Acid 01.09.01 Formulary NICE TA443
Obinutuzumab 08.02.03 Non Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Ocrelizumab 08.02.04 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ofatumumab 08.02.03 Non Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Non Formulary NICE TA381: Olaparib guidance
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Osimertinib 08.02.04 Non Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Non Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Non Formulary NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Panobinostat 08.01.05 Non Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Non Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 08.01 Non Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Non Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Non Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Non Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pemetrexed 08.01.03 Non Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Non Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Non Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Non Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Non Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.01 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 03.11 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pirfenidone 03.11 Formulary NICE TA504 Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Non Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Non Formulary NICE TA388: Pomalidomide for myeloma
Pomalidomide 08.02.04 Non Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene 06.04.01.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene 06.04.01.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Reslizumab 03.04.02 Formulary NICE TA: 479 Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab (rheumatology) 10.01.03 Non Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban 02.08.02 Formulary NICE TA 287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Non Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Non Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Secukinumab 13.05.03 Formulary NICE TA350: Plaque Psoriasis
Semaglutide 06.01.02.03 Formulary NICE NG: Type 2 diabetes in adults: management
Simeprevir 05.03.03.02 Non Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sofosbuvir 05.03.03.02 Non Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Somatropin 06.05.01 Non Formulary NICE TA188: Somatropin for growth failure in children
Somatropin 06.05.01 Non Formulary NICE TA64: Growth hormone deficiency (adults)
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.01 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Non Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Non Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.01 Non Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tofactinib 01.05.03 Formulary NICE TA547
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Non Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 01.05.03 Formulary NICE TA 456
Ustekinumab 01.05.03 Formulary NICE TA456
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Non Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Non Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Verteporfin 15mg powder for solution 11.08.02 Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vortioxetine 04.03.03 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Central Lancashire Formulary